Its primary uses are in the treatment of schizophrenia and bipolar mania. Schizophrenia In a clinical trial that compared it to haloperidol in the treatment of schizophrenia it was found to produce significantly superior overall symptom control. In another clinical trial<unk>  was compared with mosapramine and produced a similar reduction in total PANSS score, except with respect to the blunted affect part of the PANSS negative score, in which<unk>  produced a significantly greater improvement. In an open-label clinical trial comparing aripiprazole with<unk>  there was no significant difference between the two treatments discovered in terms of both efficacy and tolerability. In 2009 a clinical trial found that<unk>  produced a similar reduction of PANSS score than risperidone and the extrapyramidal side effects was similar in both frequency and severity between groups. A meta-analysis published in 2013 found that it is statistically significantly less efficacious than other second-generation antipsychotics.
Perospirone
Tiospirone
Tetherin
Survivin
Neurofilament light polypeptide
Tetraspanin
Alpha-neurotoxin
Precipitin